Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era. (Q37204440)

18 August 2017

1 reference

title

Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era. (English)

1 reference

18 August 2017

0 references

1 reference

Fernando J Bianco

1

1 reference

18 August 2017

1 July 2008

1 reference

18 August 2017

1 reference

18 August 2017

26

1 reference

18 August 2017

4

1 reference

18 August 2017

408-414

1 reference

18 August 2017

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Secondary hormonal therapy for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Clinical states in prostate cancer: toward a dynamic model of disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Epidemiology of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

20-year outcomes following conservative management of clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Natural history of progression after PSA elevation following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Prostate cancer: molecular biology of early progression to androgen independence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

The development of androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Mechanisms of androgen-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Androgen receptor signaling in androgen-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

National practice patterns and time trends in androgen ablation for localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

7 January 2021

Nomograms and medicine

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Incorporating predictions of individual patient risk in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Comparison of Cox Regression With Other Methods for Determining Prediction Models and Nomograms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.11.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLONC.2007.11.002

1 reference

18 August 2017

1 reference

PubMed ID

18593619